An Estimation of Costs of Intracoronary/Intramyocardial Injection Technology of Patient Bone Marrow Cell (BMC) Affiliated to Heart Failure in Comparison with Common Treatment Methods in Iran
Heart failure is a chronic disease that is one of the most important causes in the world. This subject puts large costs on society. The object of this study is the estimation of direct medical cost on injection technology of patient bone marrow cell affiliated to heart failure in comparison with common treatment methods in Iran.
In order to estimate treatment cost of injection technology of patient bone marrow cell affiliated to heart failure in comparison with common treatment methods, only direct medical costs were considered. The study perspective was ministry of health and providers. Costs were calculated with Excel software based on private and public tariff.
In 2016, treatment cost per capita based on public and private tariff were respectively 120 and 222 million IR Rial for bone morrow cell, 122 and 218 IR Rial for CRT, 120 and 214 for peace maker, 68 and 140 for pharmacotherapy in a one-year period, and also 138 and 233 million IR Rial for IABP in a 10 day period. Therefore, the treatment cost based on private tariff is almost among 1.7 to 2 time’s public tariff. In addition, in terms of cost, pharmacotherapy had the least and IABP had the most.
In general, the result showed that the cost of bone marrow cell had no significant difference with other treatment methods and the costs were almost similar. Therefore, it’s proposed that to enter this technology, we must notice to the effectiveness aspect and the cost effectiveness analysis must be done.
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.